TRAVERE THERAPEUTICS INC. - COMMON STOCK

Travere Therapeutics Appoints Ruth Williams-Brinkley to its Board of Directors

14 сен 2021 16:30:00 Источник Nasdaq GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

13 сен 2021 17:00:00 Источник Nasdaq GlobeNewswire

Travere Therapeutics Announces Successful Outcome from Type A Meeting with U.S. FDA for Sparsentan in Focal Segmental Glomerulosclerosis

07 сен 2021 08:00:02 Источник Nasdaq GlobeNewswire

Travere Therapeutics Announces Positive Topline Interim Results from the Ongoing Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy

16 авг 2021 07:00:02 Источник Nasdaq GlobeNewswire

Travere Therapeutics Reports Second Quarter 2021 Financial Results

29 июл 2021 16:01:00 Источник Nasdaq GlobeNewswire

Travere Therapeutics to Report Second Quarter 2021 Financial Results

22 июл 2021 16:30:00 Источник Nasdaq GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

14 июл 2021 16:30:00 Источник Nasdaq GlobeNewswire

Travere Therapeutics Announces Presentation of Abstracts at ERA-EDTA Congress 2021

04 июн 2021 08:00:00 Источник Nasdaq GlobeNewswire

Travere Therapeutics Completes Enrollment in Pivotal Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy

02 июн 2021 08:00:01 Источник Nasdaq GlobeNewswire

Travere Therapeutics to Present at Upcoming Investor Conferences

27 май 2021 16:30:00 Источник Nasdaq GlobeNewswire